| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/10/1999 | WO1999044991A1 Process for preparing a protected 4-aminomethyl-pyrrolidin-3-one |
| 09/10/1999 | WO1999044989A1 Matrix metalloproteinase inhibitors |
| 09/10/1999 | WO1999044988A2 Method for preparing sulfanyl-type endothelin receptor antagonists |
| 09/10/1999 | WO1999044987A1 NON-PEPTIDE GnRH AGENTS |
| 09/10/1999 | WO1999044981A1 Novel capsaicinoide-like substances having ester bond |
| 09/10/1999 | WO1999044943A2 Vectors and viruses used in gene therapy |
| 09/10/1999 | WO1999044642A1 Pharmaceutical compositions and their use |
| 09/10/1999 | WO1999044640A1 Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor |
| 09/10/1999 | WO1999044639A1 Remedies for brain infarction |
| 09/10/1999 | WO1999044631A1 Topical composition containing human epidermal growth factor |
| 09/10/1999 | WO1999044628A1 Conjugates useful in the treatment of prostate cancer |
| 09/10/1999 | WO1999044624A2 Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy |
| 09/10/1999 | WO1999044623A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | WO1999044621A1 Preventives/remedies for osteoporosis |
| 09/10/1999 | WO1999044620A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 09/10/1999 | WO1999044619A1 Treatment of viral disease in swine |
| 09/10/1999 | WO1999044618A1 Chemical compounds and their use to elevate pyruvate dehydrogenase activity |
| 09/10/1999 | WO1999044617A1 Activated vitamin d3 emulsion-type lotions |
| 09/10/1999 | WO1999044616A1 Steroid derived antibiotics |
| 09/10/1999 | WO1999044615A1 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism |
| 09/10/1999 | WO1999044614A1 Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption |
| 09/10/1999 | WO1999044613A1 Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin v receptors, even of v1a and v2 receptors |
| 09/10/1999 | WO1999044612A1 Substituted quinazolines and analogs and the use thereof |
| 09/10/1999 | WO1999044611A1 Triazolo-pyridazine derivatives for the treatment of chronic obstructive pulmonary diseases |
| 09/10/1999 | WO1999044610A1 Combination of a selective nmda nr2b antagonist and an opioid analgesic |
| 09/10/1999 | WO1999044608A1 New use |
| 09/10/1999 | WO1999044607A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases |
| 09/10/1999 | WO1999044606A1 Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma |
| 09/10/1999 | WO1999044605A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection |
| 09/10/1999 | WO1999044604A1 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate |
| 09/10/1999 | WO1999044603A1 Composition and method for treating macular disorders |
| 09/10/1999 | WO1999044602A1 Inflammatory cell inhibitors |
| 09/10/1999 | WO1999044601A1 Fluoxetine hydrochloride for decreasing hot flashes |
| 09/10/1999 | WO1999044600A1 Cancer management with tamoxifen and gammalinolenic acid |
| 09/10/1999 | WO1999044599A1 Therapeutic treatment for renal dysfunction |
| 09/10/1999 | WO1999044598A2 Methods for inhibiting βcell apoptosis |
| 09/10/1999 | WO1999044597A2 Use of macrolide compounds for the treatment of ards |
| 09/10/1999 | WO1999044596A2 Glycine transport inhibitors |
| 09/10/1999 | WO1999044595A2 Pharmaceutical compositions for ulcer |
| 09/10/1999 | WO1999044594A1 Fat emulsions for inhalational administration |
| 09/10/1999 | WO1999044592A1 Anti-asthma therapy |
| 09/10/1999 | WO1999044591A1 Extended release dosage form |
| 09/10/1999 | WO1999044590A1 Sustained-release preparation for aii antagonist, production and use thereof |
| 09/10/1999 | WO1999044588A2 Method for producing solid, spherical forms containing pharmaceutical active agents in a binder matrix |
| 09/10/1999 | WO1999044587A1 Apparatus and method for diluting nasal sprays containing addictive compounds |
| 09/10/1999 | WO1999044586A1 Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect |
| 09/10/1999 | WO1999044584A1 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 09/10/1999 | WO1999044581A2 Pharmaceutical composition of topiramate |
| 09/10/1999 | WO1999044578A1 Formulations with an anti-viral effect |
| 09/10/1999 | WO1999044440A1 Food compositions for preventing periodontosis or preventing the progression of periodontosis and method for preventing or treating periodontosis |
| 09/10/1999 | WO1999044425A1 Fungicide composition comprising a benzoylphenylurea |
| 09/10/1999 | WO1999037291A3 Utilization of substituted sulfonamides as antiviral agents and novel substances |
| 09/10/1999 | WO1999033850A8 NOVEL β-LACTAMASE AND DD-PEPTIDASE INHIBITORS |
| 09/10/1999 | WO1999033840A3 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha1-blocking action |
| 09/10/1999 | WO1999033793A3 Prodrugs of aspartyl protease inhibitors |
| 09/10/1999 | WO1999033451A3 Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin |
| 09/10/1999 | WO1999032514A3 Sag: sensitive to apoptosis gene |
| 09/10/1999 | WO1999032477B1 Ortho-anthranilamide derivatives as anti-coagulants |
| 09/10/1999 | WO1999032100A3 Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
| 09/10/1999 | WO1999032099A3 Use of fucane for regulating the reconstruction of connective tissues |
| 09/10/1999 | WO1999031262A3 Needle-free injection of formulated nucleic acid molecules |
| 09/10/1999 | WO1999030722A8 Pharmaceutical compositions for mucolysis and treatment of inflammation |
| 09/10/1999 | WO1999030718A3 PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL |
| 09/10/1999 | WO1999025829A3 Cdk2 protein and cdk2 protein complexes |
| 09/10/1999 | WO1999025819A3 Antisense oligonucleotides against tenascin for treating vitiligo |
| 09/10/1999 | WO1999023078A3 Novel carboxylic acid derivatives which carry amide side chains, production of said carboxylic acid derivatives and their use as endothelin receptor antagonists |
| 09/10/1999 | WO1999021617B1 Allosteric adenosine receptor modulators |
| 09/10/1999 | WO1999007718A3 Substituted tetrahydropyrane derivatives, method for producing same, their use as medicine or diagnostic agent, as well as medicine containing same |
| 09/10/1999 | WO1998053839A3 Anti-cancer products for treating cystic fibrosis |
| 09/10/1999 | WO1998005356A8 NOVEL FtsL |
| 09/10/1999 | CA2323749A1 Composition and method for treating macular disorders |
| 09/10/1999 | CA2323731A1 Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect |
| 09/10/1999 | CA2323176A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases |
| 09/10/1999 | CA2323173A1 Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma |
| 09/10/1999 | CA2323172A1 Therapeutic treatment for renal dysfunction |
| 09/10/1999 | CA2323158A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection |
| 09/10/1999 | CA2322856A1 Cancer management with tamoxifen and gammalinolenic acid |
| 09/10/1999 | CA2322854A1 Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy |
| 09/10/1999 | CA2322838A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| 09/10/1999 | CA2322796A1 Pharmaceutical compositions containing the phospholipase inhibitor sodium ¬¬3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl|oxy|acetate |
| 09/10/1999 | CA2322712A1 Method for activating natural killer (nk) cells |
| 09/10/1999 | CA2322629A1 Method for producing solid, spherical forms containing pharmaceutical active agents in a binder matrix |
| 09/10/1999 | CA2322541A1 Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta/etb-receptor antagonists |
| 09/10/1999 | CA2322493A1 Nitrate salt of anti-ulcer medicine |
| 09/10/1999 | CA2322486A1 Inflammatory cell inhibitors |
| 09/10/1999 | CA2322450A1 Formulations having an antiviral action |
| 09/10/1999 | CA2322444A1 Non-peptide gnrh agents |
| 09/10/1999 | CA2322442A1 Heterocyclic compounds as inhibitors of rotamase enzymes |
| 09/10/1999 | CA2322226A1 Method for preparing sulfanyl-type endothelin receptor antagonists |
| 09/10/1999 | CA2322207A1 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists |
| 09/10/1999 | CA2322201A1 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism |
| 09/10/1999 | CA2322164A1 Glycine transport inhibitors |
| 09/10/1999 | CA2322136A1 Glycine transport inhibitors |
| 09/10/1999 | CA2321737A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | CA2321685A1 Combination of a selective nmda nr2b antagonist and an opioid analgesic |
| 09/10/1999 | CA2321648A1 Fluoxetine hydrochloride for decreasing hot flashes |
| 09/10/1999 | CA2321171A1 Conjugates useful in the treatment of prostate cancer |
| 09/10/1999 | CA2320757A1 New use |
| 09/10/1999 | CA2319426A1 Triazolo-pyridazine derivatives for the treatment of chronic obstructive pulmonary diseases |
| 09/10/1999 | CA2318896A1 Fungicide composition comprising a benzoylphenylurea |